通过USP14的小分子抑制剂增强蛋白酶体活性
Byung-Hoon Lee1, Min Jae Lee, Soyeon Park
1Department of Cell Biology, Harvard Medical School, 240 Longwood Avenue, Boston, Massachusetts 02115, USA.
Nature
|September 11, 2010
概括
USP14是一种蛋白酶相关酶,抑制蛋白质降解. 抑制USP14增强了蛋白质酶的活性,促进了神经退行性疾病中涉及的有毒蛋白质的清除,并改善了细胞对氧化应激的抵抗力.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 神经科学是一个神经科学.
背景情况:
- 蛋白质体对于降解无处不在的蛋白质至关重要,但它们的调节是复杂的,并未完全理解.
- USP14是一种与蛋白质体相关联的二基化酶,表明它在调节蛋白质降解中的作用.
- 异常蛋白质积累与神经退行性疾病和蛋白质毒性压力有关.
研究的目的:
- 研究USP14在调节蛋白质酶介导蛋白质降解中的作用.
- 确定和描述USP14.的小分子抑制剂.
- 评估USP14抑制在增强蛋白质酶功能和减轻蛋白质毒性压力的治疗潜力.
主要方法:
- 在体外和细胞测试中评估USP14的二基化和抑制活性.
- 高通量查以识别人体选择性小分子抑制剂USP14.
- 用USP14抑制剂进行细胞治疗,以分析蛋白酶体基质降解和氧化应激抵抗.
主要成果:
- 发现USP14可以抑制乌比奎丁蛋白合物的降解.
- 一种具有催化不活性的USP14变体显示抑制活性降低,证实了deubiquitination的作用.
- 鉴定出一种选择性小分子抑制剂USP14.
- 抑制USP14增强了与神经退行性疾病相关的蛋白质酶基质的降解.
- 抑制USP14加速了氧化蛋白质的清除,增加了对氧化应激的抵抗力.
结论:
- USP14作为蛋白质酶介导蛋白质降解的负调节剂.
- 抑制USP14的deubiquitinating活性可以增强蛋白质酶的功能.
- 抑制USP14代表了特征为蛋白质毒性压力和异常蛋白质积累的条件的潜在治疗策略,包括神经退行性疾病.
相关概念视频
02:18The Proteasome
10.2K
Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
10.2K
01:52Eukaryotic Transcription Inhibitors
11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
02:18The Proteasome
4.6K
No description available
4.6K
01:13The Proteasome
1.7K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.7K
01:17The Proteasome Structure
1.7K
The ubiquitin-proteasome pathway is a well-known mechanism utilized by eukaryotic cells to remove cytoplasmic proteins that are misfolded, damaged, or no longer needed. In this pathway, the protein that needs to be eliminated undergoes a process called ubiquitination, where a chain of ubiquitin molecules is attached to the 48th lysine residue of the target protein. This ubiquitin modification helps the proteasome distinguish between a target protein and a healthy protein.
The proteasome is an...
The proteasome is an...
1.7K
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
626
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
626